Purpose: Anal fissure is caused by a pathological contraction of the internal anal sphincter. Lateral internal sphincterotomy remains the gold standard for the treatment of fissure. Botulinum toxin injections have been proposed to treat this condition without any risk of permanent injury of the internal sphincter. We investigate clinical and pathological variables and the effects of different dosage regimens of botulinum toxin to induce healing in patients with idiopathic anal fissure. Methods: This is a retrospective study at a single center. The patients underwent a pre-treatment evaluation that included clinical inspection of the fissure and anorectal manometry. We collected and analyzed demographic data, pathological variables, associated pathological conditions, and treatment variables. Success was defined as healing of the fissure, and improvement of symptoms was defined as asymptomatic persistent fissure. Results: The findings of 1003 patients treated with botulinum toxin injections were reported. At 2 months evaluation, complete healing was evident in 780 patients (77.7%). Resting anal tone (77.1 ± 18.9 mmHg) was significantly lower from baseline (P < 0.0001) and from 1-month value (P = 0.0008). Thirty-nine not healed patients underwent lateral internal sphincterotomy, and 184 were re-treated with 50 UI of botulinum toxin. In these patients, the healing rate was 93.9% (171 patients). Dose and injection site of toxin correlates with healing rate. There were no relapses during an average of about 71 months. Conclusion: Our data show that injection of botulinum toxin into the internal anal sphincter is a safe and effective alternative to surgery in patients with chronic anal fissure.
Human and animal rights: Every patient has given permission for publication of information from the medical history as long as it is used for medical research purposes. Informed consent: Informed consent was obtained from all the individual participants of the study.
Early risk stratification in acute pancreatitis is essential to guide clinical management and resource allocation. This study evaluated and compared the performance of the Bedside Index of Severity in Acute Pancreatitis (BISAP) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores in predicting disease severity and in-hospital mortality. We conducted a retrospective multicenter cohort study including 450 consecutive patients admitted with acute pancreatitis between 2016 and 2025. BISAP and APACHE II scores were calculated within the first 24 h of admission. Disease severity was classified according to the revised Atlanta classification. Discriminative ability was assessed using receiver operating characteristic (ROC) curve analysis with area under the curve (AUC) comparison. Multivariate logistic regression was performed to identify independent predictors of severe disease and mortality. The overall in-hospital mortality rate was 9.1%. Both BISAP and APACHE II scores were significantly associated with disease severity and mortality. ROC analysis demonstrated good discriminative performance for both scores, with a trend toward higher accuracy for BISAP (AUC 0.89 vs. 0.82 for mortality; P = 0.08). BISAP showed higher sensitivity and negative predictive value (100%), whereas APACHE II demonstrated lower sensitivity but comparable negative predictive value (97%). On multivariate analysis, BISAP remained a strong independent predictor of mortality (OR 2.10, 95% CI 1.65–2.68, P < 0.001) and severe disease, alongside age, comorbidities, and fever at admission. APACHE II also showed an independent but weaker association. Both BISAP and APACHE II are effective tools for early risk stratification in acute pancreatitis. BISAP offers high sensitivity and excellent negative predictive value, supporting its role as a practical screening tool at admission, while APACHE II may provide complementary value for risk refinement. These findings support an integrated approach combining simple bedside assessment with comprehensive clinical evaluation.